Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00145236
Status:
COMPLETED
Last Update Posted:
2005-09-14
First Post:
2005-09-01
Brief Title:
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
Sponsor:
Mylan Bertek Pharmaceuticals
Organization:
Mylan Bertek Pharmaceuticals
Study Overview
Official Title:
A Double-Blind Multicenter Randomized Placebo-Controlled Parallel Group Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to determine if nebivolol is superior to placebo for the treatment of elevated blood pressure in Black patients with mild to moderate hypertension
Detailed Description:
This study was a Phase II 12-week multicenter randomized double-blind parallel group placebo-controlled study of nebivolol over a range of doses in Black patients with mild to moderate hypertension Treatment was administered once daily qd for 12 weeks The study consisted of 2 phases 1 screeningwashoutsingle-blind placebo run-in and 2 randomizationtreatment Patients had 7 scheduled clinic visits during the study 6 clinic visits for patients not on current antihypertensive medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None